Medtronic (MDT) Stock Overview
Develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
MDT passed our risk checks.
MDT Community Fair Values
Create NarrativeSee what 210 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Medtronic plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$76.21 |
| 52 Week High | US$106.33 |
| 52 Week Low | US$74.40 |
| Beta | 0.63 |
| 1 Month Change | -13.40% |
| 3 Month Change | -24.45% |
| 1 Year Change | -9.54% |
| 3 Year Change | -13.96% |
| 5 Year Change | -39.36% |
| Change since IPO | 52,275.49% |
Recent News & Updates
Narrative Update • May 05
MDT: New Product Pipeline And 2027 Outlook Will Support Future Re Rating
Medtronic's analyst fair value estimate has been trimmed by about $1 to $108 as analysts recalibrate price targets across the Street, with many citing updated models, slightly adjusted long term growth and margin assumptions, and mixed reactions to recent guidance. Analyst Commentary Recent Street research on Medtronic shows a split view, with several price targets trimmed while a few are nudged higher or initiated at higher levels.Seeking Alpha • Apr 24
Medtronic: Is This Dividend Aristocrat Finally A 'Buy' Before Earnings?
Summary Medtronic plc remains a medical device stalwart with a robust product portfolio but faces slow growth, high debt, and competitive pressures. I maintain a Hold rating due to a 2.76 PEG ratio, modest revenue growth, and capital deployment concerns; a further 20% price drop would improve attractiveness. Cardiac Ablation Solutions and the Stealth AXIS robotic system are current growth drivers, while HUGO faces entrenched competition and limited market share potential. Despite a 3.4% dividend yield and stable margins, MDT's high overheads, rising inventories, and sub-WACC ROIC hinder shareholder value creation. Read the full article on Seeking AlphaRecent updates
Narrative Update • May 05
MDT: New Product Pipeline And 2027 Outlook Will Support Future Re Rating
Medtronic's analyst fair value estimate has been trimmed by about $1 to $108 as analysts recalibrate price targets across the Street, with many citing updated models, slightly adjusted long term growth and margin assumptions, and mixed reactions to recent guidance. Analyst Commentary Recent Street research on Medtronic shows a split view, with several price targets trimmed while a few are nudged higher or initiated at higher levels.Seeking Alpha • Apr 24
Medtronic: Is This Dividend Aristocrat Finally A 'Buy' Before Earnings?
Summary Medtronic plc remains a medical device stalwart with a robust product portfolio but faces slow growth, high debt, and competitive pressures. I maintain a Hold rating due to a 2.76 PEG ratio, modest revenue growth, and capital deployment concerns; a further 20% price drop would improve attractiveness. Cardiac Ablation Solutions and the Stealth AXIS robotic system are current growth drivers, while HUGO faces entrenched competition and limited market share potential. Despite a 3.4% dividend yield and stable margins, MDT's high overheads, rising inventories, and sub-WACC ROIC hinder shareholder value creation. Read the full article on Seeking AlphaNarrative Update • Apr 20
MDT: New Product Pipeline And 2027 Framework Will Support Re Rating Potential
Analysts have trimmed the Medtronic fair value estimate by about $1.50 to $109.08 as they recalibrate price targets around slightly softer revenue growth assumptions, a marginally higher discount rate, and updated views from recent research that balance lowered targets at several firms with still constructive long term price-to-earnings expectations. Analyst Commentary Recent research on Medtronic clusters around a theme of recalibrated price targets, with most firms trimming their numbers while still acknowledging areas of solid execution and product opportunity.Narrative Update • Apr 05
MDT: New Product Launches And 2027 Outlook Will Drive Re Rating Potential
The updated analyst price target for Medtronic has been revised slightly lower to $110.60. Analysts generally trimmed expectations for revenue growth and applied a slightly higher discount rate, partially offset by modestly higher profit margin assumptions and a similar future P/E framework.Narrative Update • Mar 22
MDT: New Product Launches Will Drive Fiscal 2027 Re Rating Potential
Analysts have nudged Medtronic's fair value estimate slightly lower to about $111.31 from $111.69, reflecting updated models on the discount rate, long-term revenue growth, profit margins, and future P/E assumptions after recent earnings and mixed price target moves across the Street. Analyst Commentary Recent Street research on Medtronic shows a split view, with some firms trimming price targets after earnings while others are raising targets or reinstating positive ratings.Narrative Update • Mar 07
MDT: New Product Launches And PFA Uncertainty Will Shape Fiscal 2027
Medtronic's analyst price targets have edged slightly lower, with trims of about $3 to $5 across several firms to a $100 to $118 range, as analysts factor in modest upside to recent results, questions around longer term sustainability in areas like PFA, and ongoing confidence in new product launches and fiscal 2027 growth plans. Analyst Commentary Analysts are broadly aligned that Medtronic’s latest quarter and updated outlook support a constructive long term story, but they are splitting on how much upside to bake into their models and where to set price targets in the near term.Narrative Update • Feb 21
MDT: Future Performance Will Reflect New Launches And Execution Toward Fiscal 2027
Our Medtronic price target edges up to $111.77 from $110.88 as analysts factor in recent Q3 results, modestly higher modeled revenue growth and profit margins, as well as a slightly lower future P/E multiple, alongside mixed but generally constructive Street views on new product launches and fiscal 2027 growth plans. Analyst Commentary Street research around Medtronic after fiscal Q3 clusters into two camps, with bullish analysts leaning into new product momentum and fiscal 2027 plans, and more cautious voices focusing on valuation, segment mix, and how durable current growth and profit trends might be.Narrative Update • Feb 06
MDT: Future Performance Will Reflect Generational Drivers And Execution Against Higher Expectations
Medtronic's analyst price targets have inched higher, with many analysts pointing to recent Q2 revenue and EPS beats, resumed bullish coverage across several firms, and a slightly higher assumed future P/E multiple as key supports for the updated valuation. Analyst Commentary Recent research updates have tilted broadly constructive, with several firms lifting price targets and one major upgrade from a previously negative stance, but there are still areas of caution that investors are watching closely.Narrative Update • Jan 23
MDT: Future Performance Will Reflect Generational Pipeline And Steadier Operational Execution
Analysts have nudged their Medtronic price targets slightly higher, with new objectives in the roughly $112 to $118 range. They cite stronger recent Q2 results, improving organic growth trends, and a richer target P/E multiple that brings the stock closer in line with medtech peers.Narrative Update • Jan 09
MDT: Future Performance Will Reflect Generational Pipeline And Ramping Product Launch Momentum
Analysts have nudged their implied fair value for Medtronic slightly higher to about $111 per share. This reflects a modestly higher target P/E multiple supported by recent price target increases across the Street, which are tied to improving sales trends, expanding product launches, and updated models that now more closely align the stock with medtech peers.Analysis Article • Jan 05
Medtronic (NYSE:MDT) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Narrative Update • Dec 22
MDT: Future Performance Will Reflect Cardiovascular Pipeline And New Surgical Platform Momentum
Medtronic's analyst price target has moved moderately higher toward a range of roughly $114 to $118, as analysts point to consistent Q2 revenue and EPS beats, accelerating cardiovascular and top line growth, and a strengthening product pipeline that supports sustained mid single digit plus organic growth. Analyst Commentary Analyst commentary around Medtronic has turned more constructive as recent quarters have demonstrated improving revenue performance, consistent EPS outperformance, and clearer visibility into an accelerating growth trajectory supported by the product pipeline.Narrative Update • Dec 08
MDT: Future Performance Will Reflect Cardiovascular Momentum And Emerging Product Execution Risks
Analysts have nudged our Medtronic fair value estimate higher to $111.05 from $109.82, reflecting a wave of price target increases following better than expected Q2 sales and EPS, confidence in mid single digit plus organic growth, and strengthening new product and cardiovascular momentum. Analyst Commentary Street research following the Q2 print has turned more constructive on Medtronic, with a cluster of price target increases and at least one notable rating upgrade framing the debate around the durability of mid single digit plus organic growth and improving execution.Analysis Article • Nov 28
Medtronic plc Just Recorded A 13% EPS Beat: Here's What Analysts Are Forecasting Next
Investors in Medtronic plc ( NYSE:MDT ) had a good week, as its shares rose 3.8% to close at US$105 following the...Narrative Update • Nov 24
MDT: Expect Future Performance To Reflect New Products And Evolving Corporate Focus
Medtronic's fair value estimate has been raised from $101.13 to $109.82 per share. This reflects analysts' view that accelerating sales growth, improved guidance, and sustained operational progress support a higher valuation.Narrative Update • Nov 08
MDT: Focus Will Shift To Board Changes And New Committee Impact
Medtronic's analyst price target has recently increased, with updated targets rising as high as $115. This reflects analysts' growing optimism about the company due to anticipated revenue growth, positive investor engagement, and confidence in its product pipeline and execution.Narrative Update • Oct 24
Robotic Surgery And Digital Health Will Shape Leadership In Global Markets
Medtronic's analyst price target has risen modestly, increasing from approximately $99.90 to $101.13. Analysts cite healthy expectations for upcoming quarterly results and improving sentiment in the medical technology sector.Narrative Update • Oct 10
Robotics And Digital Health Will Expand Global Reach
Medtronic's analyst price target has increased slightly to approximately $99.90, as analysts cite improved sector sentiment, recent company developments, and opportunities identified in Medtronic's product pipeline and market positioning. Analyst Commentary Recent research notes have shown a mixture of optimism and caution regarding Medtronic's outlook.Analysis Article • Sep 03
Medtronic's (NYSE:MDT) Solid Earnings Are Supported By Other Strong Factors
Even though Medtronic plc's ( NYSE:MDT ) recent earnings release was robust, the market didn't seem to notice. Our...Narrative Update • Aug 27
Robotics And Digital Health Will Expand Global Reach
Analysts have raised Medtronic’s price target to $98.44, citing activist involvement, operational improvements, and favorable policy developments, though some concerns about execution remain. Analyst Commentary Bullish analysts have raised price targets on expectations that Elliott Management's active involvement and the addition of independent directors will sharpen Medtronic's strategic focus and drive stronger growth initiatives.Analysis Article • Jul 07
Medtronic's (NYSE:MDT) Returns On Capital Are Heading Higher
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Analysis Article • Jun 16
A Look At The Fair Value Of Medtronic plc (NYSE:MDT)
Key Insights Medtronic's estimated fair value is US$101 based on 2 Stage Free Cash Flow to Equity With US$87.27 share...Analysis Article • May 30
Medtronic (NYSE:MDT) Will Pay A Larger Dividend Than Last Year At $0.71
Medtronic plc's ( NYSE:MDT ) periodic dividend will be increasing on the 11th of July to $0.71, with investors...Seeking Alpha • Apr 21
Medtronic: One Of The Best Times To Buy
Summary Medtronic offers a compelling long-term investment opportunity with solid revenue and earnings growth, driven by innovation in the cardiovascular, neuromodulation, and diabetes care segments. Medtronic's 3.4% dividend yield is well-supported by earnings, and management continues to invest in R&D to drive shareholder returns. With a forward P/E of 15.1 versus a historical norm of 18.2, MDT is attractively valued amidst improving margins and demographic tailwinds from an aging population. Read the full article on Seeking AlphaSeeking Alpha • Mar 27
Medtronic: A Great Business, But With Low Growth
Summary Medtronic is rated as a HOLD due to its underperformance, slight overvaluation, and low financial growth, despite a diverse product portfolio. The company's low volatility and stable growth make it a good option for reducing portfolio volatility, with a beta of 0.80. Financial growth concerns include a low CAGR in revenue, net income, and FCF, alongside a high FCF payout ratio. Intrinsic value calculations suggest the stock is valued at a premium, supporting the HOLD rating, but future growth potential remains, due to ongoing innovation. Read the full article on Seeking AlphaSeeking Alpha • Mar 20
Medtronic: Strength In Cardiac Ablation Solutions, Upgrade To Buy
Summary Upgraded Medtronic to a ‘Buy’ rating with a fair value of $105 per share, driven by strong growth in Cardiac Ablation Solutions and TAVR markets. Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth, highlighting significant momentum in its Cardiac Ablation Solutions business. The company’s structural heart business, especially the Evolut FX+ TAVR system, is showing strong adoption and competitive advantages over Edwards Lifesciences’s SAPIEN TAVR product. Despite challenges in China, Medtronic’s diversified portfolio and strategic M&A are expected to drive 5% organic revenue growth and 20bps annual margin expansion. Read the full article on Seeking AlphaNew Narrative • Feb 17
Medtronic Stock: A Compelling Buy for Value and Income Investors as Robotics, Innovation Catalysts Ignite Upside to $105+
Strengths and Competitive Advantages:Diverse Product Portfolio: Medtronic operates across four key segments—Cardiovascular, Medical-Surgical, Neuroscience, and Diabetes—providing revenue stability andSeeking Alpha • Feb 15
Medtronic: Several Reasons For Optimism Before The Upcoming Earnings Release
Summary Medtronic's strong fundamentals, consistent earnings surprises, and accelerating YoY revenue growth support my optimism for the upcoming earnings release and reinforce the "Buy" rating. The company's innovation in robotics and AI, along with increased R&D spending, positions Medtronic well for future growth and market leadership. Valuation analysis using P/E ratio and DDM approach indicates that Medtronic is undervalued by 22%, with a fair share price of $111. Read the full article on Seeking AlphaShareholder Returns
| MDT | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -1.8% | -2.5% | 0.5% |
| 1Y | -9.5% | -22.5% | 25.4% |
Return vs Industry: MDT exceeded the US Medical Equipment industry which returned -22.5% over the past year.
Return vs Market: MDT underperformed the US Market which returned 25.4% over the past year.
Price Volatility
| MDT volatility | |
|---|---|
| MDT Average Weekly Movement | 3.2% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MDT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MDT's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 95,000 | Geoff Martha | www.medtronic.com |
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products.
Medtronic plc Fundamentals Summary
| MDT fundamental statistics | |
|---|---|
| Market cap | US$98.63b |
| Earnings (TTM) | US$4.61b |
| Revenue (TTM) | US$35.48b |
21.2x
P/E Ratio2.8x
P/S RatioIs MDT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDT income statement (TTM) | |
|---|---|
| Revenue | US$35.48b |
| Cost of Revenue | US$12.36b |
| Gross Profit | US$23.12b |
| Other Expenses | US$18.51b |
| Earnings | US$4.61b |
Last Reported Earnings
Jan 23, 2026
Next Earnings Date
Jun 03, 2026
| Earnings per share (EPS) | 3.59 |
| Gross Margin | 65.16% |
| Net Profit Margin | 13.00% |
| Debt/Equity Ratio | 56.9% |
How did MDT perform over the long term?
See historical performance and comparisonDividends
3.7%
Current Dividend Yield79%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/13 04:10 |
| End of Day Share Price | 2026/05/13 00:00 |
| Earnings | 2026/01/23 |
| Annual Earnings | 2025/04/25 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medtronic plc is covered by 56 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kadambari Daptardar | Accountability Research Corporation |
| Harshit Gupta | Accountability Research Corporation |
| David Toung | Argus Research Company |